This site is intended for US healthcare professionals.

Clinically meaningful response after 2 or more prior systemic therapies1

Clinically meaningful response after 2 or more prior systemic therapies1

  • Double the ORR (18% vs 8%)1
  • Durable response rates1,2
Duration of response curve showing 71% of responders still responding to FOTIVDA at 12 months compared with sorafenib
Duration of response curve showing 71% of responders still responding to FOTIVDA at 12 months compared with sorafenib
  • mDOR: NR (95% CI: 9.8, NR) with FOTIVDA vs 5.7 months (95% CI, 5.6, NR) with sorafenib2
  • DCR was 73% for FOTIVDA and 65% for sorafenib1
  • OS: HR 0.97 (95% CI; 0.75, 1.24)*2

Explore safety and tolerability.

Learn More

Reach out to an AVEO
Oncology Account
Manager.

Get in Touch

Get patient support and
access via AVEO ACE.

Learn More

*Based on the Cox proportional hazards model stratified by International Metastatic RCC Database Consortium prognostic score and prior therapy.

CI=confidence interval; DCR=disease control rate; HR=hazard ratio; mDOR=median duration of response; NR=not reached; ORR=objective response rate; OS=overall survival; RCC=renal cell carcinoma.

References: 1. Rini BI, Pal SK, Escudier BJ, et al. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. Lancet Oncol. 2020;21(1):95-104. 2. FOTIVDA (tivozanib) (package insert]. Boston, MA: AVEO Pharmaceuticals, Inc, August 2024.